Peakdale announces the appointment of 'industry figurehead' Terry Hart in order to drive further medicinal chemistry capabilities and enhance its range of services.
Terry Hart brings a wealth of medicinal chemistry knowledge to Peakdale, with an industry pedigree of over 20 years of pharmaceutical experience.
This new role has been created to add further value to customers' drug discovery activities and, as medicinal chemistry services director, Hart will apply the latest medicinal chemistry knowledge and his extensive drug discovery experience to further support pharmaceutical and biotech customers' drive for new drugs.
Hart joins Peakdale from the Novartis Institute for Biomedical Research where he was unit head of discovery chemistry for seven years.
While there he co-invented several compounds that are currently in clinical trials for pain, anxiety and depression.
He has previous experience as director of medicinal chemistry within the biotech industry where he invented Rapid (rational approach to protease inhibitor design), a patented combinatorial mapping and protease inhibitor design technology.
Prior to this position, he spent 17 years at Rhone-Poulenc Rorer, in both the UK and France, where he designed and synthesised several clinical candidates, was programme leader for the Taxotere programme, and became chemistry programme director, cardiovascular research.
Kimberley Morrison, CEO of Peakdale Molecular, commented, "We are very pleased to welcome Terry to our team.
"His appointment is a major step in Peakdale's drive to further support our customers' research programmes.
"In addition to his exceptional industry experience, he is a renowned expert in medicinal chemistry and his knowledge and expertise will support Peakdale's dedicated team of medicinal chemists to meet the demand for high quality drug discovery chemistry".
Hart added, "I'm looking forward to joining Peakdale at such an exciting time.
"I have long looked upon the company as a top provider of chemistry innovation.
"I intend to significantly develop Peakdale's medicinal chemistry capabilities and offer additional value to Peakdale's clients".
Peakdale Molecular was founded in 1992.
Today, the company's customers include global pharmaceutical majors and an increasing number of biotechnology companies.
Its team of chemists combines experience in pharmaceutical R and D and process development, fine chemicals, parallel synthesis and medicinal chemistry to deliver unique chemistry solutions to a range of drug discovery challenges.
Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis and contract research chemistry.
